Section 1 of 6
Terms and abbreviations
1 evidence topic · 0 sources
| Abbreviation | Term |
|---|---|
| AE | Adverse event |
| AHFS | American Hospital Formulary Service |
| ALT | Alanine aminotransferase |
| ANCOVA | Analysis of covariance |
| AST | Aspartate aminotransferase |
| BMD | Bone mineral density |
| BSC | Best supportive care |
| C7D1 | Cycle 7, day 1 |
| CI | Confidence interval |
| CNS | Central nervous system |
| CYP3A4 | Cytochrome P450 3A4 |
| EAP | Expanded access protocol |
| FDA | U.S. Food and Drug Administration |
| GIST | Gastrointestinal stromal tumor |
| Gr | Grade |
| H1 | Histamine H1 receptor |
| H2 | Histamine H2 receptor |
| ICC | Intraclass correlation coefficient |
| ICER | Incremental cost-effectiveness ratio |
| IgE | Immunoglobulin E |
| IQWiG | Institute for Quality and Efficiency in Health Care |
| ISM | Indolent systemic mastocytosis |
| ISM-SAF | Indolent Systemic Mastocytosis Symptom Assessment Form |
| ITT | Intention to treat |
| KIT | KIT receptor tyrosine kinase |
| MC | Mast cell |
| MC-QoL | Mastocytosis Quality of Life Questionnaire |
| MS2D2 | Mastocytosis Symptom Severity Daily Diary |
| NCCN | National Comprehensive Cancer Network |
| NDA | New Drug Application |
| NonAdvSM | Nonadvanced systemic mastocytosis |
| PBO | Placebo |
| PDUFA | Prescription Drug User Fee Act |
| PGIS | Patient Global Impression of Severity |
| Pts | Patients |
| QALY | Quality-adjusted life-year |
| QD | Once daily |
| SD | Standard deviation |
| SM | Systemic mastocytosis |
| SSM | Smoldering systemic mastocytosis |
| TKI | Tyrosine kinase inhibitor |
| TRAE | Treatment-related adverse event |
| TSS | Total symptom score |